P ¼ .03), but it was not significantly associated with an increase in total number of complications in the whole cohort (OR, 1.37; 95% CI, 0.86-2.17; P ¼ .17) or in the symptomatic (OR, 1.47; 95% CI, 0.51-4.27; P ¼ .46) or asymptomatic (OR, 1.36; 95% CI, 0.81-2.28; P ¼ .23) groups. The presence of an ulcer was not able to predict the development of neurologic complications (transient ischemic attack, minor and major stroke, neurologic death) in symptomatic (OR, 1.30; 95% CI, 0.23-7.41; P ¼ .75) and asymptomatic (OR, 1.50; 95% CI, 0.68-3.30; P ¼ .30) patients.
IP119.
Early and Long-Term Results of Viabahn Endograft for Treatment of Supra-Aortic Trunk Aneurysm* Paola Wiesel, Domenico Angiletta, Giovanni Mastrangelo, Cristina Galeandro, Raffaele Pulli. University of Bari, Bari, Italy
Objective: The objective of this study was to evaluate early and longterm results of the Viabahn endograft (W. L. Gore & Associates, Flagstaff, Ariz) in the treatment of supra-aortic trunk (SAT) aneurysm.
Methods: A retrospective study from 2009 to 2017 was conducted in our institution. Thirteen patients matched the inclusion criteria in the indexed period. Patients' characteristics and early and long-term results were recorded in a dedicated database.
Results: A total of 13 SAT aneurysms (3 female and 10 male patients) were treated: 8 of the subclavian artery, 2 of the internal carotid artery, 2 of the common carotid artery, and 1 of the vertebral artery. The cause was post-traumatic in four cases (30%), related to vasculitis in two (15%), and atherosclerotic in seven (55%). Indication for surgical treatment was dimension and presence of symptoms. Four patients (30%) experienced compression symptoms, six (46%) were treated in an emergency setting (three for pain and three for rupture), and three patients (24%) were asymptomatic. All the subclavian artery aneurysms were treated through a surgical exposure of the ipsilateral brachial artery; in the remaining patients, a percutaneous femoral approach was performed (38%). Technical success was 100%, and no early complications were recorded. In all cases, postoperative therapy consisted of dual antiplatelet therapy (clopidogrel 75 mg and aspirin 100 mg) for 6 months followed by a single antiplatelet drug (aspirin 100 mg). Mean follow-up was 3.5 years (0-8 years). We performed a duplex ultrasound scan of the SAT at 1 month, 6 months, and 12 months and then every year. Primary patency was 100%; one patient had an asymptomatic occlusion of the subclavian endograft after 4 years, whereas all the other endografts were patent at the last follow-up. No cranial nerve injuries were reported, and stroke-free survival rate was 100%. No aneurysm-related death occurred. One patient died after 3 years of pulmonary cancer.
Conclusions: The Viabahn graft, even if it is considered off-label for the treatment of SAT aneurysms, provided, in our experience, acceptable early and long-term results because of its conformability and flexibility. In our opinion, the endovascular approach with this type of stent graft is technically feasible with low complication rates.
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IP121. Early Carotid Endarterectomy in Symptomatic Patients*
Cristina Galeandro, Domenico Angiletta, Paola Wiesel, Marco Petruzzellis, Raffaele Pulli. University of Bari, Bari, Italy
Objective: The objective of this study was to evaluate whether early carotid endarterectomy (CEA) in symptomatic patients is associated with higher rates of stroke or death in the postoperative period.
Methods: A retrospective study from 2016 to 2017 was conducted in our institution. In the indexed period, 68 patients matched the inclusion criteria. Patients' characteristics and results were recorded in a dedicated database. All patients were submitted to a preoperative and postoperative clinical examination by an independent neurologist and were divided into four groups based on the surgical timing (0-7 days; 7-15 days; 15-30 days; >30 days). National Institutes of Health Stroke Scale score was also calculated in all cases. In all patients, the level of serologic and intraplaque ST2 (suppression of tumorigenicity) was evaluated as a potential marker of plaque instability. Data were analyzed with c 2 test and Kaplan-Meier curves (SPSS 24.0 statistical software; IBM Corp, Armonk, NY).
Results: Of 68 patients treated, 47 were male (69%), with a median age of 70 years (range, 48-83 years); 82% suffered from hypertension, and 29% were diabetic patients. Preoperative symptoms consisted of transient ischemic attack (43%), minor stroke (32%), major stroke (23%), and crescendo transient ischemic attack (2%). Degree of stenosis was between 60% and 80% in 63% of the patients, between 80% and 99% in 27%, and near occlusion in 10%. CEA was performed in 100% of cases with a National Institutes of Health Stroke Scale score between 0 and 8: 8 (12%) eversion CEAs and 60 (88%) CEAs with patch. Eleven patients (16%) were treated within 7 days; 24 (35%) were assigned to the second group (7-15 days), 12 (18%) to the third group (15-30 days), and 21 (31%) to fourth group. No neurologic events or deaths were recorded at 30 days. There was no statistical difference between the four groups regarding ST2 marker levels. In the median follow-up of 12 months (range, 1-24 months), stroke-free survival rate was 100%.
Conclusions: The time between neurologic event and CEA did not influence the early and midterm results in our series. Early CEA may be safely proposed also in patients with major stroke.
